CASI Pharmaceuticals (CASIF) Change in Account Payables (2022 - 2025)

CASI Pharmaceuticals has reported Change in Account Payables for 4 years, with the latest figure at $560000.0 in Q3 2025.

• For the quarter ending Q3 2025, Change in Account Payables fell 68.25% year-over-year to $560000.0; the trailing twelve-month figure through Sep 2025 stood at $560000.0 (down 68.25% YoY), and the FY2025 full-year result was -$1.7 million, down 160.89% from the prior year.
• Change in Account Payables for Q3 2025 stood at $560000.0, down from $805000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $4.4 billion in Q4 2023, with the low at $560000.0 in Q3 2025.
• Historically, Change in Account Payables has averaged $880.9 million across 4 years, with a median of $3.0 million in 2022.
• Annual changes were most pronounced in 2024 — Change in Account Payables plunged 99.94% — and 2025, when it surged 204874.27%.
• CASI Pharmaceuticals' Change in Account Payables stood at $3.3 million in 2022, then jumped by 134834.63% to $4.4 billion in 2023, then sank by 99.94% to $2.7 million in 2024, then sank by 79.43% to $560000.0 in 2025.
• The last three Change in Account Payables figures came in at $560000.0 (Q3 2025), $805000.0 (Q2 2025), and $1.2 billion (Q1 2025), per Business Quant data.